Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
FDA Approvals
FDA Approvals
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
Read More
FDA Approvals
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
Read More
FDA Approvals
FDA Approved Abrysvo, First RSV Vaccine for Immunizing Pregnant Women, as Prophylaxis Against RSV Infection in Infants
Read More
FDA Approvals
Tyruko First Biosimilar for the Treatment of Relapsing Forms of Multiple Sclerosis
Read More
FDA Approvals
FDA Approved Aphexda, in Combination With Filgrastim, to Mobilize Stem Cells for Transplant in Patients With Multiple Myeloma
Read More
FDA Approvals
Temodar Receives FDA Approval for New and Updated Indications and Doses Through the Project Renewal Program
Read More
FDA Approvals
Ojjaara FDA Approved for Treatment of Myelofibrosis and Anemia
Read More
FDA Approvals
Exxua, a First-in-Class Oral Selective 5-HT1A Receptor Agonist, FDA Approved for Major Depressive Disorder
Read More
FDA Approvals
FDA Approves Pombiliti Plus Opfolda for Treatment of Pompe Disease
Read More
FDA Approvals
Tofidence, First Biosimilar to Actemra, FDA Approved for Rheumatoid Arthritis and 2 Forms of Juvenile Idiopathic Arthritis
Read More
1
2
3
4
Page 1 of 30
Results 1 - 10 of 291